Imugene Limited (ASX:IMU) director Charles Walker has shown his support for the company's medical technology strategy by purchasing shares on-market.
Walker purchased 354,340 shares in the company for an indirect interest on March 6 with a total value of more than £4,516.
He now holds 28,187,210 shares with 25 million of these in a direct interest and the remainder in an indirect interest.
Imugene is focused on developing immuno-oncology treatments CF33 and PD1-Vaxx in first-in-human studies as well as continued enrolment of its HER-Vaxx phase-2 study.
CF33 has been shown to efficiently shrink injected tumours and distant non-injected tumours in human triple-negative breast cancer, colon cancer, ovarian cancer xenograft models in mice without adverse effects.
The company’s PD1-Vaxx is a B-cell immunotherapy, peptide cancer vaccine designed to treat tumours such as lung cancer and will be trialled on patients in 2020.
HER-Vaxx is a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer with Phase 2 studies underway.